What type of study is this?

This research is Trending!

September 5, 2025New England Journal of Medicine

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension

View Full Paper

Ask AI

Bookmark

Baxdrostat reduced systolic blood pressure by an average of 14.5 mm Hg in patients taking the 1-mg dose, indicating effective blood pressure control.
With the 2-mg dose, the average reduction in systolic blood pressure was 15.7 mm Hg compared to an average of only 5.8 mm Hg in the placebo group.
A total of 796 patients were randomized, demonstrating robustness in the trial’s findings and extensive participant engagement.
The results suggest that baxdrostat could be an important addition to treatments for difficult-to-treat hypertension, although monitoring for potassium levels is necessary.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase 3 trial shows baxdrostat significantly lowers systolic blood pressure in patients with uncontrolled hypertension, indicating potential for improved management.

Cite This Study

Flack et al. (2025) studied this question.

synapsesocial.com/papers/68bb3a2b2b87ece8dc95484f https://doi.org/10.1056/nejmoa2507109

View Full Paper

Ask AI

Bookmark

Implication

Phase 3 trial shows baxdrostat significantly lowers systolic blood pressure in patients with uncontrolled hypertension, indicating potential for improved management.

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension

Key Points

Discussion

Implication

Cite This Study

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider